IP
AXSM icon

Intellectus Partners’s Axsome Therapeutics AXSM Stock Holding History

Intellectus Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,400
Closed -$36K – 280
2018
Q3 		$36K Hold
10,400
– – 0.01% 374
2018
Q2 		$33K Buy
10,400
+1,400
+16% +$4.34K 0.01% 376
2018
Q1 		$22K Buy
+9,000
New +$26.9K 0.01% 419

Other funds holding AXSM

ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Intellectus Partners's AXSM Position: Q4 2018 in Review

Intellectus Partners sold out of Axsome Therapeutics (AXSM) in Q4 2018, closing a stake of 10,400 shares — an estimated $36K sold.

Intellectus Partners first reported a position in AXSM in Q1 2018 and held it in 3 quarters. The position peaked at $36K in Q3 2018. 35 funds tracked by Wall St. Rank hold AXSM as of Q4 2018.

  • Intellectus Partners reported no remaining Axsome Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Intellectus Partners sold 10,400 Axsome Therapeutics shares in Q4 2018, an estimated $36K.
  • Intellectus Partners first reported a position in Axsome Therapeutics in Q1 2018 and held it in 3 quarters.
  • Intellectus Partners's Axsome Therapeutics position peaked at $36K in Q3 2018.
  • 35 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.